Luanne Novello serves as the Vice President of Clinical Operations at Aravive, Inc., where she leverages over thirty years of extensive experience in drug development, clinical operations, and regulatory affairs to drive the success of innovative therapies. Her leadership has been instrumental in advancing the...
Luanne Novello serves as the Vice President of Clinical Operations at Aravive, Inc., where she leverages over thirty years of extensive experience in drug development, clinical operations, and regulatory affairs to drive the success of innovative therapies. Her leadership has been instrumental in advancing the company’s mission to develop transformative treatments for patients with cancer. Under her guidance, the Clinical Operations team successfully completed enrollment and achieved a rapid database lock for a pivotal Phase 3 Biologics License Application (BLA) enabling trial in ovarian cancer, a significant milestone that underscores her expertise in orchestrating complex clinical trial operations.
In her current role, Luanne is not only focused on executing high-stakes clinical trials but is also actively involved in strategic planning for additional Phase 3 global programs while managing two concurrent Phase 1/2 studies. Her adeptness in project management and her keen understanding of oncology clinical research enable her to navigate the intricacies of clinical development with precision and foresight. Luanne’s commitment to quality management and adherence to Good Clinical Practice (GCP) standards ensures that all clinical operations are conducted with the utmost integrity and compliance.
Luanne’s skill set extends beyond clinical trial management; she excels in negotiation and team building, fostering a collaborative environment that empowers her teams to thrive. Her focus on patient-reported outcomes reflects her dedication to enhancing the patient experience throughout the clinical trial process. As a leader, she is not only driving business profitability but also shaping the future of oncology research, making her a pivotal figure in the biopharmaceutical landscape.
